<DOC>
	<DOCNO>NCT01472601</DOCNO>
	<brief_summary>This study parallel translational study Randomized Phase III trial Investigating Role Oxaliplatin duration ( 6 Cycles Versus 12 Cycles ) modify FOLFOX-6 Regimen Adjuvant Therapy Patients Stage II/III Colon Cancer ( MIDAS trial : protocol NCCCTS-467 ) . Patients participate trial provide informed consent parallel study , peripheral blood tumor tissue sign consent collect germline polymorphism analysis gene expression profile study .</brief_summary>
	<brief_title>A Prospective Study Pharmacogenetic Factors Gene Expression Profile</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>Curatively resect , histologically confirm colon adenocarcinoma ( presence inferior pole tumor peritoneal reflection ) AJCC/UICC highrisk stage II , stage III colon cancer Stage II patient high risk relapse , fulfill one follow criterion : ( T4 tumor , bowel obstruction perforation , vascular lymphatic perineural invasion ) Patients participate randomize phase II trial FOLFOX 6 12 cycle Patients sign write informed consent translational study participate randomize phase III study investigate role oxaliplatin duration ( 6 cycle versus 12 cycle ) modify FOLFOX6 regimen adjuvant therapy patient stage II/III colon cancer Patients agree sample peripheral blood genetic analysis Patients consider suitable study investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>